Paper Details
- Home
- Paper Details
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
Author: CiceroArrigo F G, ErtekSibel, TartagniElisa
Original Abstract of the Article :
Despite the proven efficacy of statins, they are often reported to be inadequate to achieve low-density lipoprotein cholesterol (LDL-C) goals (especially in high-risk patients). Moreover, a large number of subjects cannot tolerate statins or full doses of these drugs. Thus, there is a need for addit...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1517/14712598.2014.902929
データ提供：米国国立医学図書館（NLM）
Evolocumab: A Novel Inhibitor of PCSK9 for Low-Density Lipoprotein Cholesterol Reduction
The field of [cardiology] is constantly seeking [innovative therapies] to manage [hyperlipidemia], particularly [high low-density lipoprotein cholesterol (LDL-C)] levels. This research explores the [efficacy and safety profile] of [evolocumab (AMG145)], an [injectable inhibitor of the proprotein convertase subtilisin/kexin type 9 (PCSK9)], in reducing [LDL-C] levels. The study highlights the potential of [evolocumab] as an [adjunctive therapy] for patients who are [unable to achieve LDL-C goals with statins alone] or [intolerant to statins].
Evolocumab Shows Significant LDL-C Reduction Potential
The research demonstrates the [significant efficacy] of [evolocumab] in [reducing LDL-C levels]. The study found that [evolocumab] effectively [lowered LDL-C] in patients who were [unable to achieve LDL-C goals with statins alone], demonstrating its potential as a valuable tool for [managing high-risk patients] with [hyperlipidemia].
A Promising New Approach for Managing Hyperlipidemia
This research offers a [new avenue] for [managing hyperlipidemia] and improving [cardiovascular health]. [Evolocumab] represents a significant advancement in [treatment options] for patients who are [unable to tolerate or achieve adequate results with traditional statin therapy]. This study encourages [further research and clinical trials] to explore the long-term benefits and optimal use of [evolocumab] in managing [hyperlipidemia].
Dr.Camel's Conclusion
This research is a promising oasis in the vast desert of [hyperlipidemia research], offering a new tool for [reducing LDL-C] and potentially improving [cardiovascular health] for many patients. The findings suggest that [evolocumab] could play a significant role in [managing high-risk patients] who are [unable to achieve LDL-C goals with statins alone].
Date :
- Date Completed 2014-12-29
- Date Revised 2019-12-10
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.